MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
2020 ACC/AHA Guideline for Management of Patients With Valvular Heart Disease
Experts share their views on how these new guidelines will impact practice.
With Gorav Ailawadi, MD; Mario J. Garcia, MD, FACC; Rishi Puri, MD, PhD; and Vinod H. Thourani, MD
Contemporary Issues in TAVR
By James McCabe, MD, and Darren Mylotte, MD
How Do OCT and IVUS Differ?
A comparison and assessment of these modern imaging modalities.
By Joshua Waggoner, MD, and Marc D. Feldman, MD, FACC, FSCAI
Update on Near-Infrared Spectroscopy/Intravascular Ultrasound
The fundamental aspects and current clinical roles.
By Selcuk Kucukseymen, MD; Francesca Ciatti, MD; Niccolò Ciardetti, MD; Alessio Mattesini, MD; and Carlo Di Mario, MD, PhD
Potential Use of OCT Imaging in Clinical Practice
From preintervention to postprocedure follow-up, the utility of optical coherence tomography assessment is examined.
By Daniel Chamié,, MD, and Ricardo A. Costa, MD, PhD
High-Resolution Lesion Assessment With OCT
What every interventional cardiologist needs to know about this FDA-approved imaging modality.
By Sahil A. Parikh, MD, and Marco A. Costa, MD, PHD
Novel Nonpharmacologic Therapies for Patients With Refractory Angina Pectoris
A review of available treatment options.
By Francesco Gallo, MD; Francesco Ponticelli, MD; Antonio Colombo, MD; and Francesco Giannini, MD
Clinical Implications and Treatment of Coronary Microvascular Obstruction in STEMI
The unmet need of effectively targeting MVO to improve clinical outcomes.
By Rocco A. Montone, MD, PhD, and Filippo Crea, MD, PhD, FESC, FACC
The CoreValve Program
Cardiac Interventions Today interviews Carlos E. Ruiz, MD, PhD, who shares his expertise on the current status of the CoreValve device and trial data.
IVUS With Virtual Histology in Clinical Practice
A novel imaging technology for assessing vulnerable plaque.
By Adnan Khalid, MD, and Steven P. Marso, MD
Identification of Vulnerable Plaques
Various imaging methods allow evaluation in vivo.
By Daisuke Nakamura, MD; Setsu Nishino, MD, PhD; Guilherme F. Attizzani, MD; Hiram G. Bezerra, MD, PhD; and Marco A. Costa, MD, PhD
PCI for the Left Main Coronary Artery
With the availability of drug-eluting stents (DES) and the dramatic reduction in restenosis rates they have provided, the results of left main coronary artery (LMCA) stenting have certainly improved compared to preliminary experiences with bare-metal stents (BMS), which were limited by high restenosis rates and sudden deaths.1-6 Encouraging results have been reported at midterm clinical follow-up in some observational registries with elective DES implantation in the LMCA, with a 1-year mortality rate of 0% to 5%.7-12 In these registries, the need for target lesion revascularization (TLR) varied from 0% to 14%, and target vessel revascularization (TVR) varied from 0% to 19%.
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC, and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Structural Heart Interventions
By Ted E. Feldman, MD, FESC, FACC, FSCAI
PCI Strategies After Fibrinolytic Therapy
How to choose the appropriate reperfusion strategy.
By Michel R. Le May, MD